Edition:
Deutschland

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.81USD
20 Oct 2017
Change (% chg)

$-0.00 (-0.52%)
Prev Close
$0.81
Open
$0.81
Day's High
$0.82
Day's Low
$0.80
Volume
53,672
Avg. Vol
164,586
52-wk High
$4.30
52-wk Low
$0.62

TROV.OQ

Chart for TROV.OQ

About

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 1 analysts

Overall

Beta: 0.37
Market Cap(Mil.): $31.68
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

BRIEF-Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders‍​

* Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders‍​ - SEC Filing Source text: (http://bit.ly/2fELxf1) Further company coverage:

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage:

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

BRIEF-Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

* Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

BRIEF-Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075

* Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor

BRIEF-CVI Investments Inc reports 5.7 percent passive stake in Trovagene as of July 13 - SEC filing

July 24 CVI Investments Inc. Reports 5.7 Pct Passive Stake In Trovagene Inc

BRIEF-Sabby Management reports 5.70 percent passive stake in Trovagene

* Sabby Management LLC reports 5.70 percent passive stake in Trovagene Inc as of July 13 - sec filing Source text : http://bit.ly/2uwdR7Z Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.25%
Rohstoffe +0.25%
Industrie -0.07%
Konjunktur abhängige Waren & Dienstleistungen -0.32%
Konjunktur unabhängige Waren & Dienstleistungen +0.39%
Finanzindustrie -0.04%
Pharma +0.50%
Technologie -0.21%
Telekommunikation -0.14%